- Home
- RDN vs GPCR Comparison
RDN vs GPCR Comparison
Compare RDN & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | RDN | GPCR |
|---|---|---|
| Founded | 1977 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.8B |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | RDN | GPCR |
|---|---|---|
| Price | $36.21 | $20.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $43.57 | ★ $107.29 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0M |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | ★ 5.61 | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $1,197,084,000.00 | N/A |
| Revenue This Year | $92.73 | N/A |
| Revenue Next Year | $7.66 | N/A |
| P/E Ratio | $20.38 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.53 | $20.50 |
| 52 Week High | $41.05 | $94.90 |
Technical Indicators
Market Signals| Indicator | RDN | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.49 | 24.31 |
| Support Level | $35.89 | $20.73 |
| Resistance Level | $37.23 | $57.15 |
| Average True Range (ATR) | 0.81 | 1.21 |
| MACD | 0.24 | 0.61 |
| Stochastic Oscillator | 82.83 | 7.96 |
Price Performance
Historical ComparisonAbout RDN Radian Group Inc.
Radian Group Inc is engaged in mortgage and real estate services. It provides both credit-related mortgage insurance coverage and other products and services across the residential real estate and mortgage finance industries. It has one reportable segment, Mortgage Insurance, which primarily derives its revenue by providing private mortgage insurance on residential first-lien mortgage loans to mortgage lending institutions and mortgage credit investors.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.